URISPAS

This brand name is authorized in France, Hong Kong, Ireland, Lithuania, Netherlands, Singapore, Turkey, United Kingdom, South Africa

Active ingredients

The drug URISPAS contains one active pharmaceutical ingredient (API):

1 Flavoxate UNII 9C05J6089W - FLAVOXATE HYDROCHLORIDE

Flavoxate is an antispasmodic selective to the urinary tract. Flavoxate has been shown to have a direct antispasmodic action on smooth muscle fibres. Read about Flavoxate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
URISPAS Film-coated tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G04BD02	Flavoxate	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 63383409
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 163298, 166796, 175981, 196214, 23544
Country: HK	Department of Health Drug Office	Identifier(s): 40153
Country: IE	Health Products Regulatory Authority	Identifier(s): 58590, 58595
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1014237
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 15032
Country: SG	Health Sciences Authority	Identifier(s): 12007P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699559090567
Country: ZA	Health Products Regulatory Authority	Identifier(s): 29/18/0428